Beijing Luzhu Biotechnology Co (HKSE:02480) GF Value : HK$0.00 (As of May. 26, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-26), Beijing Luzhu Biotechnology Co's share price is HK$23.90. Beijing Luzhu Biotechnology Co's GF Value is HK$0.00. Therefore, Beijing Luzhu Biotechnology Co's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Beijing Luzhu Biotechnology Co is Not Valued.

Beijing Luzhu Biotechnology Co (HKSE:02480) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Beijing Luzhu Biotechnology Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	23.90	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co GF Value Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Executives

Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Zhang Yanping	2202 Interest of your spouse
Kong Jian	2101 Beneficial owner
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines